Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (60)

III-01Gilbert Koch

A multi-response model for rheumatoid arthritis based on delay differential equations in collagen induced arthritic mice treated with an anti-GM-CSF antibody

Thursday 09:50-11:05

III-02Julia Korell

Modelling red blood cell survival data

Thursday 09:50-11:05

III-03Elke Krekels

Maturation of glucuronidation; a system specific property

Thursday 09:50-11:05

III-04Steve Kuan

Population Pharmacokinetic Modeling of Investigational Agent MLN4924 in Cancer Patients

Thursday 09:50-11:05

III-05Ryuji Kubota

A Novel Framework of Long-term Prediction of integrase inhibitors for treatment naïve patients

Thursday 09:50-11:05

III-06Anna Largajolli

Meal Tolerance Test (MTT): Nonlinear Mixed-Effects Modeling of Insulin Secretion

Thursday 09:50-11:05

III-07Marc Lavielle

Improved diagnostic plots require improved statistical tools. Implementation in MONOLIX 4.0

Thursday 09:50-11:05

III-08Robert Leary

Exact Reproducibility of Population PK/PD NLME Numerical Results across Different Computational Environments

Thursday 09:50-11:05

III-09Donghwan Lee

Development of a population model to describe diurnal and chronokinetic variation in cilostazol pharmacokinetics

Thursday 09:50-11:05

III-10Annabelle Lemenuel Diot

External evaluation of a Hepatitis C viral kinetic model which links viral dynamics to sustained virologic response (SVR)

Thursday 09:50-11:05

III-11Natacha Lenuzza

Development of a PK library of parent drug/metabolite integrated models

Thursday 09:50-11:05

III-13

Development of a longitudinal model for characterizing adverse events of psychiatric drugs in routine clinical care

Thursday 09:50-11:05

III-16Arianna Madrid Aispuro

Modelling the sleep effects of Zolpidem in rats using non-homogeneous Markov chain models

Thursday 09:50-11:05

III-17Paolo Magni

A new population PK/PD model to assess the myelotoxicity of candidate drugs in preclinical and in clinical studies

Thursday 09:50-11:05

III-18Eleonora Marostica

Population state-space modelling of patient responses in antidepressant studies

Thursday 09:50-11:05

III-19Hafedh Marouani

Kinetic nomograms assist individualization of drug regimens

Thursday 09:50-11:05

III-20Amelie Marsot

Population pharmacokinetics of Phenobarbital in neonates and infants.

Thursday 09:50-11:05

III-21Maria Matoses Osborne

Ex Vivo modeling of the apoptotic effects of Vivia009 and its metabolite in patients with Chronic Lymphocytic Leukemia

Thursday 09:50-11:05

III-22Hugh McDevitt

Technology Roadmap to Support Model Based Drug Development

Thursday 09:50-11:05

III-23Christophe Meille

PK/PD Model of skin toxicity in animal reported as binary outcome

Thursday 09:50-11:05

III-24France Mentré

Comparison of results of the different software for design evaluation in population pharmacokinetics and pharmacodynamics

Thursday 09:50-11:05

III-25François Mercier

A Bayesian meta-analysis of longitudinal lesion count data in multiple sclerosis patients

Thursday 09:50-11:05

III-26Evgeny Metelkin

A Systems Pharmacology Model of Anandamide Dynamics After FAAH Inhibitor Administration

Thursday 09:50-11:05

III-27Enrica Mezzalana

Title: Quantitative Assessment of First Night Effect in a Polysomnographic Insomnia Study through a Multinomial Mixed-Effect Markov-Chain Model

Thursday 09:50-11:05

III-28Dirk Jan Moes

Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients on a calcineurin inhibitor free regimen

Thursday 09:50-11:05

III-29Jonas Bech Møller

Model-based Analysis of the GLP-1 Response Following an Oral Glucose Tolerance Test (OGTT)

Thursday 09:50-11:05

III-30

Predicting the Gemcitabine efficacy by a stochastic language based model

Thursday 09:50-11:05

III-31Flora Musuamba-Tshinanu

KPD modelling of trough FEV1 in chronic obstructive pulmonary disease (COPD).

Thursday 09:50-11:05

III-32Thu Thuy Nguyen

Evaluation of Fisher information matrix using Gaussian quadrature in nonlinear mixed effects models: application to dose-response trials

Thursday 09:50-11:05

III-33Thu Thuy Nguyen

Designing a dose-response study analysed by nonlinear mixed effects models

Thursday 09:50-11:05

III-34Ronald Niebecker

Importance of study design for estimation of Vmax and Km characterising nonlinear monoclonal antibody clearance

Thursday 09:50-11:05

III-35

Development of a detailed physiologically based computational kidney model to describe the renal excretion of hydrophilic agents in rats

Thursday 09:50-11:05

III-36Elisabet Nielsen

PK/PD Indices of Antibiotics Predicted by Mechanism-Based PKPD Models

Thursday 09:50-11:05

III-37Valerie Nock

Leukopenia following triple high-dose chemotherapy and stem cell rescue

Thursday 09:50-11:05

III-38Joakim Nyberg

Parallelization in optimal experimental design using PopED

Thursday 09:50-11:05

III-39Joakim Nyberg

Population optimal design with correlation using Markov Models

Thursday 09:50-11:05

III-40Kayode Ogungbenro

A semi-mechanistic gastric emptying pharmacokinetic model for 13C-octanoic acid: an evaluation using simulation

Thursday 09:50-11:05

III-41Oliver Ackaert

Population modelling of blood pressure: assessing clinically important factors for cardiovascular diseases

Thursday 09:50-11:05

III-42Erik Olofsen

Population Analysis of Kalman-Filtered Permutation Entropy of the Electroencephalogram

Thursday 09:50-11:05

III-43Itziar Oteo

Differences among six prevalent creatinine clearance calculation methods by covariate modeling of CL for Netilmicin using NONMEM for inference

Thursday 09:50-11:05

III-44Zinnia Parra-Guillen

Target Mediated Drug Disposition Model to Describe the Expression and Kinetics of IL12 And IFNγ in Gene Therapy

Thursday 09:50-11:05

III-45

Dried Blood Spots and Sparse Sampling: A perfect combination for minimally invasive PK/PD studies in children

Thursday 09:50-11:05

III-46

A Mechanistic Model for the Effects of A Novel Drug on Glucose, Glucagon and Insulin Applied to Adaptive Phase II Design

Thursday 09:50-11:05

III-47Mark Penney

Using Mechanistic Modelling of Cyclic Neutropenia to Predict the Effects of a COPD Therapeutic on Systemic Neutrophil Levels

Thursday 09:50-11:05

III-48Henry Pertinez

Physiologically based, POP-PK modelling of Strontium Ranelate in the ovariectomised rat disease model of post menopausal osteoporosis.

Thursday 09:50-11:05

III-49Kirill Peskov

A Quantitative Systems Pharmacology Model Provides Insights into Phosphate Homoeostasis through Multiple Interacting Pathways

Thursday 09:50-11:05

III-50Kirill Peskov

Systems Modeling of EphB4/ephrinB2 Signaling Pathways

Thursday 09:50-11:05

III-51Klas Petersson

Assessment of bias in model parameter estimates of continuous time Markov models for categorical data

Thursday 09:50-11:05

III-52Olivier Petricoul

From Animal to Human with a new monoclonal antibody: An example of the use of pharmacokinetics only to assist on the choice of first in human dose.

Thursday 09:50-11:05

III-53Chiara Piana

Impact of non-adherence to antiretroviral therapy in HIV-infected children

Thursday 09:50-11:05

III-54

Development of a PBPK model of doxorubicin

Thursday 09:50-11:05

III-56Venkatesh Pilla Reddy

Exposure-Response Relationship of Typical and Atypical Antipsychotics Assessed by the Positive and Negative Syndrome Scale (PANSS) and its Subscales

Thursday 09:50-11:05

III-57Gregory Pinault

A structured approach to industrialize the data sourcing to support model based drug development

Thursday 09:50-11:05

III-58Bart Ploeger

Confirmation of symptomatic and disease modifying effects of levodopa using the ELLDOPA study

Thursday 09:50-11:05

III-59Italo Poggesi

Efficiency criteria generated by optimal design tools should be evaluated in the light of study objectives

Thursday 09:50-11:05

III-60Klaas Prins

Modeling urge urinary incontinence data acknowledging non-Poisson dispersion of counts within individual provides a major model fit improvement.

Thursday 09:50-11:05

III-61Klaas Prins

Use of a generalized poisson model to describe micturition frequency in patients with overactive bladder disease.

Thursday 09:50-11:05

III-63Dinko Rekic

Bilirubin – a biomarker of atazanavir exposure in HIV/AIDS patients

Thursday 09:50-11:05

III-64Elba Romero

PK/PD sampling design optimization following a sustained release formulation of triptorelin using optimal experimental design

Thursday 09:50-11:05

III-65

Population PK/PD Modeling of a Hepatitis C NS3 Inhibitor

Thursday 09:50-11:05